Key result
Pancreatic renin-angiotensin systems are implicated in the pathogenesis of diabetes, pancreatitis, and pancreatic cancer, highlighting the therapeutic potential for RAS antagonism.
Why the study?
Does renin-angiotensin system antagonism have therapeutic potential in pancreatic diseases such as diabetes, pancreatitis, and pancreatic cancer?
Does renin-angiotensin system antagonism have therapeutic potential in pancreatic diseases such as diabetes, pancreatitis, and pancreatic cancer?
Local pancreatic renin-angiotensin systems are implicated in pancreatic diseases, suggesting RAS antagonism may have untapped therapeutic potential for conditions like diabetes and pancreatitis.
Local pancreatic RAS may influence diabetes and cancer; leaves open targeted therapies pending mechanistic trials.
BACKGROUND: In addition to the circulating (endocrine) renin-angiotensin system (RAS), local renin-angiotensin systems are now known to exist in diverse cells and tissues. Amongst these, pancreatic renin-angiotensin systems have recently been identified and may play roles in the physiological regulation of pancreatic function, as well as being implicated in the pathogenesis of pancreatic diseases including diabetes, pancreatitis and pancreatic cancer. AIM: To review and summarise current knowledge of pancreatic renin-angiotensin systems. METHODS: We performed an extensive PubMed, Medline and online review of all relevant literature. RESULTS: Pancreatic RAS appear to play various roles in the regulation of pancreatic physiology and pathophysiology. Ang II may play a role in the development of pancreatic ductal adenocarcinoma, via stimulation of angiogenesis and prevention of chemotherapy toxicity, as well as in the initiation and propagation of acute pancreatitis (AP); whereas, RAS antagonism is capable of preventing new-onset diabetes and improving glycaemic control in diabetic patients. Current evidence for the roles of pancreatic RAS is largely based upon cell and animal models, whilst definitive evidence from human studies remains lacking. CONCLUSIONS: The therapeutic potential for RAS antagonism, using cheap and widely available agents, and may be untapped and such roles are worthy of active investigation in diverse pancreatic disease states.
No takes yet. Share an insight, caveat, or question.
Skipworth et al. (2011) conducted a review in Pancreatic diseases (diabetes, pancreatitis, pancreatic cancer). Pancreatic renin-angiotensin systems and RAS antagonism was evaluated. Pancreatic renin-angiotensin systems are implicated in the pathogenesis of diabetes, pancreatitis, and pancreatic cancer, highlighting the therapeutic potential for RAS antagonism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: